AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1540491 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-R-nitrendipine 20 mg
Number of subjects: 6
Study 1540491 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-S-nitrendipine 20 mg
Number of subjects: 6
Study 1540491 — intervention group
Group type: COMPARATOR
Intervention: R,S-nitrendipine (pseudoracemic mixture of 10 mg (+)-R and 10 mg (-)-S)
Number of subjects: 6
Study 1540491 — intervention group
Group type: EXPERIMENTAL
Intervention: R-nitrendipine
Number of subjects: 6
Study 1540491 — intervention group
Group type: EXPERIMENTAL
Intervention: S-nitrendipine
Number of subjects: 6
Study 1540491 — intervention group
Group type: EXPERIMENTAL
Intervention: Major pyridine metabolite M1
Number of subjects: 6
Study 4001300 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally provided program of social support counselling
Number of subjects: 0
Study 4001300 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31982540 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular paracetamol
Number of subjects: 0
Study 31982540 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol as-needed
Number of subjects: 0
Study 31982540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29804552 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified report intervention
Number of subjects: 110
Study 29804552 — intervention group
Group type: COMPARATOR
Intervention: Standard report control
Number of subjects: 110
Study 26435472 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 0
Study 26435472 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (IDet)
Number of subjects: 0
Study 26543177 — intervention group
Group type: EXPERIMENTAL
Intervention: v‐gel supraglottic airway device (SGAD)
Number of subjects: 33
Study 26543177 — intervention group
Group type: COMPARATOR
Intervention: endotracheal tube (ETT)
Number of subjects: 33
Study 24075125 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 75
Study 24075125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22057726 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 7185
Study 19147639 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical chloramphenicol (n=488)
Number of subjects: 972
Study 19147639 — intervention group
Group type: COMPARATOR
Intervention: Paraffin ointment (n=484; placebo)
Number of subjects: 972
Study 16785075 — intervention group
Group type: EXPERIMENTAL
Intervention: Citracal tablet providing 315 mg of elemental calcium
Number of subjects: 36
Study 16785075 — intervention group
Group type: EXPERIMENTAL
Intervention: OsCal tablet providing 500 mg of elemental calcium
Number of subjects: 36
Study 16785075 — intervention group
Group type: EXPERIMENTAL
Intervention: People's Choice tablet providing 600 mg of elemental calcium
Number of subjects: 36
Study 16785075 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablet
Number of subjects: 36
Study 15479445 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergence, curl, mean and Gaussian curvatures of the flow field combined with skin line direction
Number of subjects: 0
Study 11034038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phytonadione 2.5 mg
Number of subjects: 30
Study 11034038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9063425 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant combination (ADC) - brompheniramine maleate-phenylpropanolamine hydrochloride
Number of subjects: 59
Study 9063425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9063425 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant combination (ADC)
Number of subjects: 59
Study 7981078 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-P (melphalan and prednisone)
Number of subjects: 281
Study 7981078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (Peptichemio, vincristine, and prednisone)
Number of subjects: 281
Study 7981078 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-P
Number of subjects: 281
Study 7981078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 281
Study 7981078 — intervention group
Group type: COMPARATOR
Intervention: MPH-P and combination chemotherapy
Number of subjects: 281
Study 2662452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan alone (n = 315)
Number of subjects: 615
Study 2662452 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan and metronidazole (n = 300)
Number of subjects: 615
Study 4527847 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPA (cyclophosphamide, cytosine arabinoside, prednisolone, and L asparaginase)
Number of subjects: 71
Study 4527847 — intervention group
Group type: COMPARATOR
Intervention: CAP (cyclophosphamide, cytosine arabinoside, and prednisolone)
Number of subjects: 71
Study 4527847 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPA
Number of subjects: 71
Study 30597537 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral intervention
Number of subjects: 39
Study 30597537 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 39
Study 28355113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (62 Gy in 20 fractions in 5 weeks)
Number of subjects: 168
Study 28355113 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (80 Gy in 40 fractions in 8 weeks)
Number of subjects: 168
Study 26135582 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dispensing pharmacist as an integral member of a primary care team
Number of subjects: 10000
Study 26135582 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist in a community pharmacy with predefined training in performing medication reviews
Number of subjects: 10000
Study 26135582 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist in a community pharmacy (care as usual)
Number of subjects: 10000
Study 24691455 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex critical care ventilator (Group B and C)
Number of subjects: 51
Study 24691455 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex critical care ventilator (Group C)
Number of subjects: 51
Study 24691455 — intervention group
Group type: COMPARATOR
Intervention: Conventional mini-ventilator (Group A)
Number of subjects: 51
Study 22759218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based home care (HBHC)
Number of subjects: 60
Study 22759218 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 60
Study 20097330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vague feedback about performance
Number of subjects: 0
Study 20097330 — intervention group
Group type: COMPARATOR
Intervention: Precise feedback about performance
Number of subjects: 0
Study 18192779 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in primary HIV infection
Number of subjects: 0
Study 18192779 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy of a limited duration
Number of subjects: 0
Study 18192779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention strategy
Number of subjects: 0
Study 18192779 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARTAC trial
Number of subjects: 0
Study 15910348 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with epinephrine 1:200,000 and clonidine 2 microg.kg‐1 (group-C)
Number of subjects: 30
Study 15910348 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine with epinephrine 1:200,000 (group-NC)
Number of subjects: 30
Study 12911201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg x kg(‐1)) and propofol (1.8 mg x kg(‐1))
Number of subjects: 263
Study 12911201 — intervention group
Group type: COMPARATOR
Intervention: N2O/sevoflurane (4% sevoflurane in N2O at 41 x min(‐1) and oxygen at 21 min(‐1)) and propofol (1.8 mg x kg(‐1))
Number of subjects: 263
Study 12911201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 263
Study 12911201 — intervention group
Group type: COMPARATOR
Intervention: N2O/sevoflurane
Number of subjects: 263
Study 10555905 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 0
Study 10555905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9315416 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep injection of local anesthetics (n = 31), paracervical block involving four injections approximately 3 cm deep
Number of subjects: 66
Study 9315416 — intervention group
Group type: COMPARATOR
Intervention: Regular injection of local anesthetics (n = 35), paracervical block involving four injections approximately 1.5 cm deep
Number of subjects: 66
Study 9315416 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep injection of local anesthetics (n = 31)
Number of subjects: 66
Study 9315416 — intervention group
Group type: COMPARATOR
Intervention: Regular injection of local anesthetics (n = 35)
Number of subjects: 66
Study 8436146 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg t.i.d. as additive treatment to morphine
Number of subjects: 15
Study 8436146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study 8436146 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg t.i.d.
Number of subjects: 15
Study 3014855 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (500 mg elemental calcium)
Number of subjects: 24
Study 3014855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (500 mg elemental calcium)
Number of subjects: 24
Study 3014855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29162331 — intervention group
Group type: EXPERIMENTAL
Intervention: High load at 100% body weight
Number of subjects: 20
Study 29162331 — intervention group
Group type: COMPARATOR
Intervention: Low load at 20% body weight
Number of subjects: 20
Study 27574730 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning procedure on pain tolerance with belief in analgesic treatment (Experiment 1)
Number of subjects: 0
Study 27574730 — intervention group
Group type: COMPARATOR
Intervention: No previous conditioning procedure (Experiment 2)
Number of subjects: 0
Study 23039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once a day
Number of subjects: 205
Study 22726241 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4, 0.6 and/or 0.8 U/kg once daily for two 6-day periods
Number of subjects: 49
Study 20431081 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 54
Study 20431081 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultation
Number of subjects: 54
Study 18711175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 663
Study 18711175 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 663
Study 16422313 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (CARB, similar to the DASH diet)
Number of subjects: 160
Study 16422313 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in protein (PROT, predominantly from nonmeat sources)
Number of subjects: 160
Study 16422313 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in unsaturated fat (UNSAT, predominantly monounsaturated)
Number of subjects: 160
Study 12023411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 84
Study 12023411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10486370 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial Haemoccult FOB tests
Number of subjects: 150251
Study 10486370 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy or flexible sigmoidoscopy and double contrast barium enema (DCBE)
Number of subjects: 150251
Study 10486370 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 150251
Study 10486370 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic investigation
Number of subjects: 150251
Study 10486370 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for screen detected colorectal neoplasia
Number of subjects: 150251
Study 10486370 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for screen detected benign adenomas or stage A cancers
Number of subjects: 150251
Study 10486370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 150251
Study 8941691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg daily, starting from the 3rd postoperative day (14 patients)
Number of subjects: 40
Study 8941691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive Thrombocytosis (RT) group
Number of subjects: 40
Study 8941691 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 40
Study 8114172 — intervention group
Group type: EXPERIMENTAL
Intervention: ST/ET
Number of subjects: 34
Study 8114172 — intervention group
Group type: EXPERIMENTAL
Intervention: ET/ST
Number of subjects: 34
Study 8114172 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 3533127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg biphasic release formulation twice daily)
Number of subjects: 34
Study 3533127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 34
Study 30062458 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pronator quadratus repair technique involving the brachioradialis muscle insertion (test group)
Number of subjects: 28
Study 30062458 — intervention group
Group type: COMPARATOR
Intervention: Conventional radial incision through the muscle without pronator quadratus repair (standard group)
Number of subjects: 28
Study 27513404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac sodium 75 mg
Number of subjects: 150
Study 27513404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac sodium 100 mg
Number of subjects: 150
Study 27513404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diclofenac)
Number of subjects: 150
Study 24864182 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g/1.73 m2 per day for 3 days)
Number of subjects: 83
Study 24864182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 83
Study 22956705 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM-HI intervention in enhanced offices
Number of subjects: 341
Study 19193743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 91
Study 19193743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 18393014 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin
Number of subjects: 0
Study 18393014 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntocinon
Number of subjects: 0
Study 18393014 — intervention group
Group type: COMPARATOR
Intervention: No use of prostaglandin or syntocinon
Number of subjects: 0
Study 18393014 — intervention group
Group type: COMPARATOR
Intervention: Perceived risk of uterine rupture
Number of subjects: 0
Study 16316558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d for 6 months
Number of subjects: 100
Study 16316558 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 500 mg/d for 1 month
Number of subjects: 100
Study 12854625 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler with spacer
Number of subjects: 0
Study 12854625 — intervention group
Group type: COMPARATOR
Intervention: Nebuliser
Number of subjects: 0
Study 10584041 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (5 g/MJ, 19% of total energy)
Number of subjects: 18
Study 10584041 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (5 g/MJ, 19% of total energy)
Number of subjects: 18
Study 10584041 — intervention group
Group type: COMPARATOR
Intervention: Rapeseed oil (5 g/MJ, 19% of total energy)
Number of subjects: 18
Study 8651516 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual disinfection procedures using five disinfectants (two 2% alkaline glutaraldehyde preparations, 3.2% alkaline glutaraldehyde, 75 ppm iodophor, and 0.5% glutaraldehyde-0.03% phenolic)
Number of subjects: 5
Study 8651516 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual disinfectant procedures (one 2% glutaraldehyde, 3.2% glutaraldehyde, and 0.5% glutaraldehyde-0.03% phenolic) and automated disinfectant procedures (one 2% glutaraldehyde, 0.5% glutaraldehyde-0.03% phenolic, and 0.2% peracetic acid)
Number of subjects: 5
Study 8651516 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated disinfection procedures
Number of subjects: 5
Study 2009789 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized BN52021 (PAF antagonist)
Number of subjects: 21
Study 2009789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21
Study 7010650 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% HSA in Ringer's lactate solution (RL) resuscitation
Number of subjects: 36
Study 7010650 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution (RL) resuscitation
Number of subjects: 36
Study 31741252 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrator-assisted start-stop exercises, 3 times a week for 6 weeks
Number of subjects: 50
Study 31741252 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrator-assisted start-stop exercises + additional psychoeducation and mindfulness meditation, 3 times a week for 6 weeks
Number of subjects: 50
Study 31741252 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 50
Study 31741252 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional psychobehavioral intervention
Number of subjects: 50
Study 30770744 — intervention group
Group type: EXPERIMENTAL
Intervention: Free school fruit intervention (2001/2002)
Number of subjects: 1950
Study 30770744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no free fruit)
Number of subjects: 1950
Study 27914846 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide injection
Number of subjects: 147
Study 27914846 — intervention group
Group type: COMPARATOR
Intervention: 20 mg triamcinolone acetonide injection
Number of subjects: 147
Study 25246604 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction group (EG)
Number of subjects: 67
Study 25246604 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 67
Study 24092240 — intervention group
Group type: EXPERIMENTAL
Intervention: CM five-element music
Number of subjects: 170
Study 24092240 — intervention group
Group type: COMPARATOR
Intervention: Western music therapy
Number of subjects: 170
Study 24092240 — intervention group
Group type: COMPARATOR
Intervention: No music therapy
Number of subjects: 170
Study 22972168 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA alone (A group)
Number of subjects: 216
Study 22972168 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA + MTX (B group)
Number of subjects: 216
Study 22972168 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA + MTX + other DMARDs (C group)
Number of subjects: 216
Study 22972168 — intervention group
Group type: COMPARATOR
Intervention: ADA + other DMARDs (D group)
Number of subjects: 216
Study 22972168 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 216
Study 22972168 — intervention group
Group type: EXPERIMENTAL
Intervention: A, B, C groups
Number of subjects: 216
Study 22972168 — intervention group
Group type: COMPARATOR
Intervention: D group
Number of subjects: 216
Study 19756348 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 mcg
Number of subjects: 10
Study 19756348 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-34) 20 mcg
Number of subjects: 10
Study 17454663 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously disclosed memories
Number of subjects: 181
Study 17454663 — intervention group
Group type: COMPARATOR
Intervention: Previously undisclosed memories
Number of subjects: 181
Study 15118187 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (40 g protein/d)
Number of subjects: 18
Study 15118187 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (40 g protein/d)
Number of subjects: 18
Study 15118187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both soy and whey groups
Number of subjects: 18
Study 11793931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate-dimeglumine
Number of subjects: 27
Study 11793931 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 27
Study 9498442 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated chikungunya virus (CHIKV) vaccine
Number of subjects: 0
Study 9498442 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VEEV vaccine
Number of subjects: 0
Study 9498442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7919944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg to 50 mg)
Number of subjects: 114
Study 7919944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 7919944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 114
Study 7919944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine and Placebo
Number of subjects: 114
Study 2838231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 X 1 mg/day for 1 week)
Number of subjects: 22
Study 2838231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2838231 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 age-matched children not suffering from asthma)
Number of subjects: 22
Study 30411986 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototoxic regimen of psoralen ultraviolet A (PUVA)
Number of subjects: 40
Study 30411986 — intervention group
Group type: COMPARATOR
Intervention: Potent intralesional corticosteroids
Number of subjects: 40
Study 28566363 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with cytology in triage of HPV positives (new policy)
Number of subjects: 42752
Study 28566363 — intervention group
Group type: COMPARATOR
Intervention: Cervical cytology with HPV test in triage of low-grade cytological abnormalities (old policy)
Number of subjects: 42752